6-K
Eltek Ltd (ELTK)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission file number 000-28884
Eltek Ltd.
(Name of Registrant)
Sgoola Industrial Zone, Petach Tikva, Israel
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Eltek Ltd.
EXPLANATORY NOTE
On August 14, 2025 Eltek issued a press release reporting second quarter 2025 financial results. A copy of this press release is furnished herewith as Exhibit 99.1.
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Press Release: Eltek Ltd. Reports 2025 Second Quarter<br> Financial Results |
| --- | --- |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ELTEK LTD. |
|---|
| (Registrant) |
| By: /s/Ron Freund |
| Ron Freund |
| Chief Financial Officer |
Date: August 14, 2025
Exhibit 99.1
Press Release
Eltek Ltd. Reports Strong Second-Quarter 2025 Results
20% Quarter-over-quarter revenue growth; gross margin expands to 24%
Petach Tikva, Israel (August 14, 2025) Eltek Ltd. (NASDAQ: ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs), today announced its financial results for the quarter ended June 30, 2025.
Second Quarter 2025 Highlights
| Q2 2025 | Q2 2024 | % | |
|---|---|---|---|
| Revenues (*) | $12.5 million | $10.5 million | +20% |
| Gross margin | 24.1% | 15.6% | +8.5% |
| Operating income | $1.5 million | $0.4 million | +259% |
| Financial income (expense) | $(1.0) million | $0.5 million | n/m |
(*) Revenues for the six months ended June 30, 2025 totaled $25.3 million, up 14% from $22.2 million in the 2024 period.
Eli Yaffe, Chief Executive Officer, stated:
“Strong momentum across our defense and medical segments drove significant year-over-year growth, highlighted by double-digit revenue increases. Continued operational improvements and a favorable product mix (compared to Q2 2024) contributed to a substantial increase in gross margin and operating profit, which reached $1.5 million - more than triple the amount recorded in the same period last year.
We remain committed to expanding our production capacity. All the equipment that was delivered to date has been successfully installed and is performing in accordance with specifications. Construction to accommodate the core of our investment plan - the new 60-meter coating lines is progressing smoothly, on schedule, and without any material impact on ongoing production operations. Following a recent scheduling update from our coating lines supplier, we have been informed of an additional delay in the delivery of the first line. We now expect the first line to arrive at our facility toward the end of 2025.
With staffing up approximately 10% since January, we continue our efforts to meet growing demand while maintaining best-in-class lead times.
The sharp appreciation of the Israeli shekel during the quarter resulted in a non-cash financial expense of $1.0 million. Given that the majority of our revenues are denominated in U.S. dollars, we have proactively updated our pricing model to better align with our NIS-based expenses. The impact of the currency fluctuation will be reflected in future customer orders, helping to protect our margins moving forward."
Second Quarter 2025 GAAP Financial Results
Revenues for the second quarter of 2025 were $12.5 million compared to $10.5 million in the second quarter of 2024.
Gross profit for the second quarter of 2025 was $3.0 million (24% of revenues) compared to $1.6 million (16% of revenues) in the second quarter of 2024.
Operating profit for the second quarter of 2025 was $1.5 million compared to operating profit of $0.4 million in the second quarter of 2024.
Financial expenses for the second quarter of 2025 were $1.0 million compared to financial income of $0.5 million in the second quarter of 2024. Financial expenses primarily resulted from the 9% erosion of the U.S. dollar against the NIS.
Net income for the second quarter of 2025 was $0.4 million or $0.05 per fully diluted share compared to net income of $0.8 million or $0.11 per fully diluted share in the second quarter of 2024.
Second Quarter 2025 Non-GAAP Financial Results
EBITDA for the second quarter of 2025 was $2.0 million (15.6% of revenues) compared to EBITDA of $0.8 million (7.6% of revenues) in the second quarter of 2024.
Six Months Ended June 30, 2025 GAAP Financial Results
Revenues for the first six months of 2025 were $25.3 million compared to $22.2 million in the first six months of 2024.
Gross profit for the first six months of 2025 was $5.2 million (21% of revenues) compared to $4.9 million (22% of revenues) in the first six months of 2024.
Operating profit for the first six months of 2025 was $2.2 million compared to operating profit of $2.1 million in the first six months of 2024.
Financial expenses for the first six months of 2025 were $0.5 million compared to financial income of $0.8 million in the first six months of 2024. Financial expenses primarily resulted from the erosion of the U.S. dollar against the NIS.
Net profit for the first six months of 2025 was $1.4 million or $0.20 per fully diluted share compared to net profit of $2.5 million or $0.38 per fully diluted share in the first six months of 2024.
Six Months Ended June 30, 2025 Non-GAAP Financial Results
EBITDA for the first six months of 2025 was a $3.1 million (12% of revenues) compared to EBITDA of $2.9 million (13% of revenues) in the first six months of 2024.
About our Non-GAAP Financial Information
The Company reports financial results in accordance with U.S. GAAP and herein provides EBITDA, a non-GAAP measure. This non-GAAP measure is not in accordance with, nor is it a substitute for, GAAP measures. This non-GAAP measure is intended to supplement the Company’s presentation of its financial results that are prepared in accordance with GAAP. The Company uses the non-GAAP measure presented to evaluate and manage the Company’s operations internally. The Company is also providing this information to assist investors in performing additional financial analysis. Reconciliation between the Company's results on a GAAP and non-GAAP basis is provided in a table below.
Conference Call
Today, Thursday, August 14, 2024, at 9:00am Eastern Time (16:00pm Israel Time, 6:00am Pacific Time), Eltek will conduct a conference call to discuss the results. The call will feature remarks by Eli Yaffe, Chief Executive Officer and Ron Freund, Chief Financial Officer.
To participate, please call the following teleconference numbers. Please allow for additional time to connect prior to the call:
| United States: | 1-866-860-9642 |
|---|---|
| Israel: | 03-918-0691 |
| --- | --- |
| International: | +972-3-918-0691 |
| --- | --- |
To Access a Replay of the Call
A replay of the call will be available for 30 days on the Investor Info section on Eltek’s corporate website at http://www.nisteceltek.com approximately 24 hours after the conference call is completed.
About Eltek
Eltek – ”Innovation Across the Board”, is a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs) and is an Israeli leading company in this industry. PCBs are the core circuitry of most electronic devices. Eltek specializes in the manufacture and supply of complex and high-quality PCBs, HDI, multilayered and flex-rigid boards for the high-end market. Eltek is ITAR compliant and has AS-9100 and NADCAP Electronics certifications. Its customers include leading companies in the defense, aerospace and medical industries in Israel, the United States, Europe and Asia.
Eltek was founded in 1970. The Company’s headquarters, R&D, production and marketing center are located in Israel. Eltek also operates through its subsidiary in North America and by agents and distributors in Europe, India, South Africa and South America.
For more information, visit Eltek's web site at www.nisteceltek.com
Forward Looking Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties including, but not limited to expected results in future quarters, the impact of the Coronavirus on the economy and our operations, risks in product and technology development and rapid technological change, product demand, the impact of competitive products and pricing, market acceptance, the sales cycle, changing economic conditions and other risk factors detailed in the Company’s Annual Report on Form 20-F and other filings with the United States Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Investor Contact
Ron Freund
Chief Financial Officer
[email protected]
+972-3-939-5023
(Tables follow)
| Eltek Ltd. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consolidated Statements of Income | ||||||||||||
| U.S dollars in thousands (except per share data) | ||||||||||||
| Three months ended | Six months ended | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 30, | June 30, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Revenues | 12,529 | 10,466 | 25,285 | 22,249 | ||||||||
| Costs of revenues | (9,510 | ) | (8,830 | ) | (20,054 | ) | (17,361 | ) | ||||
| Gross profit | 3,019 | 1,636 | 5,231 | 4,888 | ||||||||
| Research and development expenses, net | - | (47 | ) | (50 | ) | (62 | ) | |||||
| Selling, general and administrative expenses | (1,563 | ) | (1,184 | ) | (3,000 | ) | (2,700 | ) | ||||
| Operating profit | 1,456 | 405 | 2,181 | 2,126 | ||||||||
| Financial income (expense), net | (1,012 | ) | 489 | (508 | ) | 839 | ||||||
| Income before income tax | 444 | 894 | 1,673 | 2,965 | ||||||||
| Income tax expenses | 79 | 143 | 306 | 475 | ||||||||
| Net income | 365 | 751 | 1,367 | 2,490 | ||||||||
| Earnings per share: | ||||||||||||
| Basic net income per ordinary share | 0.05 | 0.11 | 0.20 | 0.38 | ||||||||
| Diluted net income per ordinary share | 0.05 | 0.11 | 0.20 | 0.38 | ||||||||
| Weighted average number of ordinary shares used to compute | ||||||||||||
| basic net income per ordinary share (in thousands) | 6,715 | 6,706 | 6,715 | 6,541 | ||||||||
| Weighted average number of ordinary shares used to compute | ||||||||||||
| diluted net income per ordinary share (in thousands) | 6,784 | 6,764 | 6,785 | 6,628 |
| Eltek Ltd. | ||||||
|---|---|---|---|---|---|---|
| Consolidated Balance Sheets | ||||||
| U.S dollars in thousands | ||||||
| June 30, | December 31, | |||||
| --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | 1,770 | 7,575 | ||||
| Short-term bank deposits | 9,385 | 9,663 | ||||
| Trade receivables (net of allowance for credit losses) | 14,480 | 11,786 | ||||
| Inventories | 12,874 | 9,488 | ||||
| Other accounts receivable and prepaid expenses | 404 | 602 | ||||
| Total current assets | 38,913 | 39,114 | ||||
| Long term assets: | ||||||
| Severance pay fund | 61 | 56 | ||||
| Deferred tax assets, net | 334 | 496 | ||||
| Operating lease right of use assets | 6,409 | 5,911 | ||||
| Total long term assets | 6,804 | 6,463 | ||||
| Property and equipment, net | 18,703 | 14,578 | ||||
| Total Assets | 64,420 | 60,155 | ||||
| Liabilities and Shareholder's equity | ||||||
| Current liabilities: | ||||||
| Trade payables | 7,197 | 7,367 | ||||
| Other accounts payable and accrued expenses | 5,527 | 5,136 | ||||
| Short-term operating lease liabilities | 1,047 | 827 | ||||
| Total current liabilities | 13,771 | 13,330 | ||||
| Long-term liabilities: | ||||||
| Accrued severance pay | 525 | 443 | ||||
| Long-term operating lease liabilities | 5,477 | 5,190 | ||||
| Total long-term liabilities | 6,002 | 5,633 | ||||
| Shareholders' equity: | ||||||
| Ordinary shares of NIS 3.0 par value – Authorized: 10,000,000 shares at June 30, 2025 and December 31, 2024;<br><br> <br>Issued and outstanding: 6,715,624 shares at June 30, 2025 and 6,714,040 shares at December 31, 2024 | 6,012 | 6,011 | ||||
| Additional paid-in capital | 32,634 | 32,627 | ||||
| Foreign currency translation adjustments | 3,750 | 664 | ||||
| Capital reserve | 2,777 | 2,507 | ||||
| Accumulated deficit | (526 | ) | (617 | ) | ||
| Total shareholders' equity | 44,647 | 41,192 | ||||
| Total liabilities and shareholders' equity | 64,420 | 60,155 |
| Eltek Ltd. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unaudited Non-GAAP EBITDA Reconciliations | ||||||||||
| U.S dollars in thousands | ||||||||||
| Three months ended | Six months ended | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 30, | June 30, | |||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||
| GAAP net income | 365 | 751 | 1,367 | 2,490 | ||||||
| Add back items: | ||||||||||
| Financial income, net | 1,012 | (489 | ) | 508 | (839 | ) | ||||
| Income tax expenses | 79 | 143 | 306 | 475 | ||||||
| Depreciation and amortization | 500 | 388 | 966 | 753 | ||||||
| Non-GAAP EBITDA | 1,956 | 793 | 3,147 | 2,879 |
| Eltek Ltd. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consolidated Statement of Cash flow | ||||||||||||
| U.S dollars in thousands | ||||||||||||
| Three months ended | Six months ended | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 30, | June 30, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Cash flows from operating activities: | ||||||||||||
| Net Income | 365 | 751 | 1,367 | 2,490 | ||||||||
| Adjustments to reconcile net income to net cash flows | ||||||||||||
| provided by operating activities: | ||||||||||||
| Depreciation | 500 | 388 | 967 | 753 | ||||||||
| Unrealized financing expenses (income), net | 595 | (98 | ) | 466 | (186 | ) | ||||||
| Share-based compensation | 132 | 154 | 270 | 286 | ||||||||
| Decrease in deferred tax assets | 120 | (100 | ) | 202 | 91 | |||||||
| 1,347 | 344 | 1,905 | 944 | |||||||||
| Decrease (increase) in operating lease right-of-use assets | (1 | ) | 2 | - | 3 | |||||||
| Decrease (increase) in trade receivables | (1,378 | ) | (219 | ) | (1,733 | ) | 517 | |||||
| Decrease (increase) in other receivables and prepaid expenses | 314 | 234 | 247 | 309 | ||||||||
| Decrease (increase) in inventories | (2,282 | ) | (169 | ) | (2,612 | ) | (565 | ) | ||||
| Increase (decrease) in trade payables | (1,138 | ) | 955 | (2,000 | ) | (536 | ) | |||||
| Increase (decrease) in other liabilities and accrued expenses | (201 | ) | (48 | ) | (28 | ) | (249 | ) | ||||
| Increase (decrease) in employee severance benefits, net | 39 | (48 | ) | 46 | (30 | ) | ||||||
| (4,647 | ) | 707 | (6,080 | ) | (551 | ) | ||||||
| Net cash provided by (used in) operating activities | (2,935 | ) | 1,802 | (2,808 | ) | 2,883 | ||||||
| Cash flows from investing activities: | ||||||||||||
| Purchase of fixed assets | (1,743 | ) | (3,215 | ) | (2,880 | ) | (5,947 | ) | ||||
| Withdrawal of (investment in) short-term bank deposits, net | - | (132 | ) | 534 | (6,534 | ) | ||||||
| Net cash used in investing activities | (1,743 | ) | (3,347 | ) | (2,346 | ) | (12,481 | ) | ||||
| Cash flows from financing activities: | ||||||||||||
| Exercise of options | 8 | 16 | 8 | 261 | ||||||||
| Dividend distribution | (1,276 | ) | - | (1,276 | ) | - | ||||||
| Issuance of shares, net | - | - | - | 9,312 | ||||||||
| Net cash provided by (used in) financing activities | (1,268 | ) | 16 | (1,268 | ) | 9,573 | ||||||
| Effect of translation adjustments | 1,250 | (204 | ) | 617 | (376 | ) | ||||||
| Net increase (decrease) in cash and cash equivalents | (4,696 | ) | (1,733 | ) | (5,805 | ) | (401 | ) | ||||
| Cash and cash equivalents at the beginning of the period | 6,466 | 10,610 | 7,575 | 9,278 | ||||||||
| Cash and cash equivalents at the end of the period | 1,770 | 8,877 | 1,770 | 8,877 |